Literature DB >> 17558597

The effects of medications on circulating levels of cardiac natriuretic peptides.

Richard W Troughton1, A Mark Richards, Tim G Yandle, Chris M Frampton, M Gary Nicholls.   

Abstract

Circulating cardiac natriuretic peptide levels are being used increasingly in a range of clinical circumstances. Since it is evident that drugs used in the treatment of cardiovascular disorders can modulate natriuretic peptide levels, we here review the literature documenting these effects. Diuretics, blockers of the renin-angiotensin system, vasodilator agents, dopamine-like agonists, amiodarone, and perhaps allopurinol and statins suppress natriuretic peptide levels, most obviously in heart failure. Beta-blockers stimulate natriuretic peptide concentrations in hypertensive subjects, whereas in heart failure they have little effect or are stimulatory in the short term and inhibitory with sustained therapy. Digitalis compounds and aspirin tend to increase natriuretic peptide levels, and calcium channel blocking agents have varying effects depending on the individual drug and duration of administration. The effects of other drugs are less clear. Additional information is needed regarding the effects of medications along with dissection of the role of altered cardiac secretion versus changes in plasma clearance as explanation for drug-induced perturbations in natriuretic peptide concentrations. In the meantime, clinicians need to consider the known effects of medications when interpreting plasma levels of the cardiac natriuretic peptides.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17558597     DOI: 10.1080/07853890701232057

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  9 in total

1.  Early NT-proBNP decrease with ivabradine in ambulatory patients with systolic heart failure.

Authors:  Luis Sargento; Milan Satendra; Susana Longo; Nuno Lousada; Roberto Palma dos Reis
Journal:  Clin Cardiol       Date:  2013-08-08       Impact factor: 2.882

Review 2.  Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials.

Authors:  Wei Xin; Zhiqin Lin; Shuhua Mi
Journal:  Heart Fail Rev       Date:  2015-01       Impact factor: 4.214

3.  Genome-wide association analysis and fine mapping of NT-proBNP level provide novel insight into the role of the MTHFR-CLCN6-NPPA-NPPB gene cluster.

Authors:  Fabiola Del Greco M; Cristian Pattaro; Andreas Luchner; Irene Pichler; Thomas Winkler; Andrew A Hicks; Christian Fuchsberger; Andre Franke; Scott A Melville; Annette Peters; H Erich Wichmann; Stefan Schreiber; Iris M Heid; Michael Krawczak; Cosetta Minelli; Christian J Wiedermann; Peter P Pramstaller
Journal:  Hum Mol Genet       Date:  2011-01-27       Impact factor: 6.150

4.  Diagnostic accuracy of plasma NT-proBNP levels for excluding cardiac abnormalities in the very elderly.

Authors:  Bert Vaes; Victoria Delgado; Jeroen Bax; Jan Degryse; Rudi G J Westendorp; Jacobijn Gussekloo
Journal:  BMC Geriatr       Date:  2010-11-11       Impact factor: 3.921

Review 5.  Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis.

Authors:  Richard W Troughton; Christopher M Frampton; Hans-Peter Brunner-La Rocca; Matthias Pfisterer; Luc W M Eurlings; Hans Erntell; Hans Persson; Christopher M O'Connor; Deddo Moertl; Patric Karlström; Ulf Dahlström; Hanna K Gaggin; James L Januzzi; Rudolf Berger; A Mark Richards; Yigal M Pinto; M Gary Nicholls
Journal:  Eur Heart J       Date:  2014-03-06       Impact factor: 29.983

Review 6.  Biomarker Development in Cardiology: Reviewing the Past to Inform the Future.

Authors:  Katharine A Kott; Michael Bishop; Christina H J Yang; Toby M Plasto; Daniel C Cheng; Adam I Kaplan; Louise Cullen; David S Celermajer; Peter J Meikle; Stephen T Vernon; Gemma A Figtree
Journal:  Cells       Date:  2022-02-08       Impact factor: 6.600

7.  Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes.

Authors:  Dermot Phelan; Chris Watson; Ramon Martos; Patrick Collier; Anil Patle; Seamas Donnelly; Mark Ledwidge; John Baugh; Ken McDonald
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

8.  Association of cardiac and renal function with extreme N-terminal fragment pro-B-type natriuretic peptide levels in elderly patients.

Authors:  Hua Cui; Guoliang Huo; Lin Liu; Li Fan; Ping Ye; Jian Cao; Yongyi Bai; Fan Wang; Yixin Hu
Journal:  BMC Cardiovasc Disord       Date:  2012-07-26       Impact factor: 2.298

Review 9.  Ivabradine, coronary artery disease, and heart failure: beyond rhythm control.

Authors:  Pietro Scicchitano; Francesca Cortese; Gabriella Ricci; Santa Carbonara; Michele Moncelli; Massimo Iacoviello; Annagrazia Cecere; Michele Gesualdo; Annapaola Zito; Pasquale Caldarola; Domenico Scrutinio; Rocco Lagioia; Graziano Riccioni; Marco Matteo Ciccone
Journal:  Drug Des Devel Ther       Date:  2014-06-03       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.